modelSulfapyridine

Diagram of Sulfapyridine

Extends from Pharmacolibrary.Drugs.ATC.J.J01EB04.

Information

name:Sulfapyridine
ATC code:J01EB04
route:oral
compartments:1
dosage:1000mg
volume of distribution:0.49L
clearance:0.024L/h/kg
other parameters in model implementation

Sulfapyridine is a sulfonamide antibacterial drug that was historically used to treat bacterial infections, particularly in the pre-penicillin era. It is a synthetic antimicrobial agent. Its use has largely declined due to the development of more effective and less toxic antibiotics, though it is sometimes still encountered as a metabolite of sulfasalazine, a drug used for rheumatoid arthritis and inflammatory bowel disease.

Pharmacokinetics

Pharmacokinetic parameters are reported for healthy adult volunteers following oral administration.

References

  1. Ma, JJ, et al., & Yao, X (2009). Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clinica chimica acta; international journal of clinical chemistry 407(1-2) 30–35. DOI:10.1016/j.cca.2009.06.025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19560446

  2. Kuhn, UD, et al., & Blume, HH (2010). Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. International journal of clinical pharmacology and therapeutics 48(1) 1–10. DOI:10.5414/cpp48001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20040334

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)